Filing summary
Entity note: The supplied filing is Flora Growth Corp.’s Form 10-Q, not a filing identified as Zerostack Corp. It covers the quarter ended March 31, 2023. Amounts below are USD millions unless stated otherwise. The company presented all periods under U.S. GAAP; it had previously reported under IFRS.
Business context and financial performance
Flora operates cannabis and pharmaceutical businesses across its House of Brands, Commercial & Wholesale, and Pharmaceuticals segments. Its portfolio includes JustCBD and Vessel, and its commercial operations include FGH, acquired in December 2022.
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $20.107 | $4.946 |
| Gross profit / margin | $5.477 / 27% | $2.670 / 54% |
| Operating expenses | $8.554 | $10.332 |
| Operating loss | $(3.077) | $(7.662) |
| Net loss | $(3.905) | $(7.630) |
| Adjusted EBITDA (non-GAAP) | $(1.436) | $(3.400) |
| Basic and diluted loss per share | $(0.03) | $(0.11) |
| Cash used in operating activities | $(4.324) | $(6.561) |
Revenue growth primarily reflected acquired businesses: JustCBD contributed $12.1 million and FGH $8.0 million in the quarter. Pharmaceuticals revenue declined to $0.4 million from $0.7 million, which management attributed to supply constraints and lower Colombian dermo-cosmetic demand. Gross margin fell substantially, principally because FGH distributes lower-margin pharmaceuticals, with additional pressure from product mix and promotions in Colombia. Lower operating expenses and higher gross profit reduced the net loss year over year.
Financial position, cash flow, and material changes
Cash was $5.259 million at March 31, 2023, down from $9.537 million at December 31, 2022. Current assets were $27.879 million and current liabilities $15.499 million, yielding working capital of approximately $12.4 million. Total assets were $77.040 million, total liabilities $23.428 million, and shareholders’ equity $53.612 million. Debt was $1.086 million, comprising a euro-denominated credit facility secured by receivables; operating lease liabilities totaled $2.855 million.
Operating cash outflow improved year over year but remained significant. Investing cash outflow was $0.102 million, compared with $15.644 million in Q1 2022, when the JustCBD acquisition used substantial cash. Financing cash outflow was $0.019 million. Trade receivables, net of a $3.024 million expected-credit-loss allowance, were $6.729 million; $2.831 million of gross trade receivables were more than 180 days past due.
Shares issued and outstanding at quarter-end were 136.938 million; 138.840 million were outstanding on May 8, 2023. Potential dilution includes options, warrants, restricted awards and contingent consideration.
Outlook, risks, contingencies, and unusual items
- Going concern: Management reported substantial doubt about the company’s ability to continue as a going concern for at least one year from issuance. It stated cash was insufficient to fund growth and meet obligations, and that additional financing may be needed. Financing availability and terms are uncertain; failure to raise funds could require curtailed or ceased operations.
- Operating outlook: No quantified revenue or earnings guidance is provided. Management expects ongoing operating losses and negative cash flows, and is evaluating cost reductions and financing alternatives. Colombian cultivation has not yet produced material cannabis export volumes; delays and regulatory hurdles may prolong cash deficiencies.
- Listing risk: Nasdaq gave the company until July 3, 2023 to regain compliance with the $1.00 minimum bid-price requirement, potentially through a reverse stock split. Failure could lead to delisting proceedings.
- Contingencies: The company recorded $2.974 million for legal disputes and $2.024 million for estimated U.S. sales tax. A $2.9 million claim involving a former FGH shareholder is covered by an indemnification agreement capped at $5.0 million; the company also recorded indemnification receivables. A separate Colombian customs and foreign-exchange inquiry opened in April 2023 presents a reasonably possible loss that the company could not estimate.
- Management and equity events: CEO and Chairman Luis Merchan resigned April 12, 2023; Hussein Rakine became CEO and a director on April 16. Merchan’s separation terms include $0.4 million severance, a health-premium payment of less than $0.1 million, and 1.6 million shares issued April 26.
- Controls: Management concluded disclosure controls were not effective as of March 31, 2023, primarily due to the material weakness described in the 2022 annual report. No material changes to internal control over financial reporting were reported during the quarter.
- Other notable items: A $0.883 million unrealized fair-value loss included an increase in JustCBD contingent purchase consideration. The Original Hemp assets were acquired in March for contingent payments with a stated maximum of $0.6 million.
Important facts for investors to verify
- How much additional capital is required, on what timeline, and whether financing can be secured without substantial dilution or restrictive debt terms.
- Cash burn, collections on aged receivables, and the assumptions supporting management’s going-concern plans.
- Whether Colombian cultivation can achieve material export sales, and the timing and regulatory requirements for doing so.
- Nasdaq bid-price compliance status and any reverse-split or delisting developments after the filing.
- The recoverability of indemnification receivables and the outcomes of the FGH-related claims, sales-tax exposure, and DIAN inquiry.
- Progress in remediating the material weakness and improving disclosure controls.
- Revenue quality and sustainable margins, given acquisition-driven growth and the reported decline in gross margin.